MEET YOUR NEW AI CLINICAL ASSISTANT /// GET EARLY ACCESS
Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.
CONTACT USUse our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities.
Leverage real-world datasets of matched molecular and clinical data with digital whole slide pathology images to uncover new insights across the research and development spectrum.
Leverage our robust biobank of patient-derived tumor organoids to accelerate drug discovery.
Integrate CDx claims into Tempus assays through a validated and established sequencing platform to pursue companion diagnostic biomarkers.
Bring discoveries from the lab to market through our full-service CRO.
Utilize NGS and EMR integrations to identify patients that match your study's eligibility criteria, including targetable biomarkers from DNA and RNA.
Our AI algorithms run on top of common diagnostics modalities and give researchers new AI-driven insights to support clinicians’ management of their individual patients and potential trial eligibility.
Leverage our end to end solutions to design and execute Tempus-sponsored clinical trials for therapeutics, devices, and diagnostics from study concept to registrational filing.
90%
of the top 20 pharma oncology companies partner with Tempus
170+
biopharma partnerships
6M+
de-identified research records to power scientific discovery to improve patient outcomes
700K+
records with matched clinical data linked with genomic information to understand driver mutations and outcomes associations
150K+
records with full transcriptomic data for interrogating tumor biology and mechanisms of action
6
NGS tests to support clinical trial and research sequencing
5K+
oncologists rely on Tempus as their precision medicine partner
10
days on average to activate a new site
200+
provider networks and research institutions in the TIME Trial® Program
20K+
patients have been identified for potential enrollment into clinical trials in our network
We spoke with Gilead experts to learn how the company uses multimodal data to achieve early successes in translational biomarker research and discovery.
Read moreHear from Janssen’s Dr. Najat Khan to find out how the company is applying advanced AI algorithms to RWD—with groundbreaking results.
Read moreRead about the experience of four organizations, who partnered with Tempus for prospective sequencing for clinical trials, retrospective sequencing and analyses, companion diagnostic development, and sponsored testing.
Read moreCombining sequencing, analytics, and data licensing with Tempus allows you to uncover new insights across R&D. Learn how one company made it happen.
Read moreRead about an example of how Tempus Multimodal Data enabled a pharmaceutical company to more quickly identify pancreatic cancer subtypes’ molecular signatures.
Read moreLearn how Sermonix Pharmaceuticals partnered with Tempus and its TIME network of clinical sites to accelerate patient recruitment for a phase 2 study.
Read moreIn this Q&A with Dr. Hisham Hamadeh of Genmab, we explore how using multimodal RWD can help organizations solve their toughest drug development challenges.
Read moreTempus is sponsoring a prospective study, titled Sculptor, in collaboration with AstraZeneca that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC) that leverages Tempus’ comprehensive portfolio of molecular profiling offerings.
READ PRESS RELEASEThe expanded collaboration bolsters GSK’s data science and AI-driven R&D efforts, providing the company access to Tempus’ AI-enabled platform to support improved clinical trial design, speed up enrollment, and identify drug targets.
READ PRESS RELEASETempus collaborating with Kartos to develop a companion diagnostic (CDx) test in support of its ongoing Phase II study of navtemadlin (KRT-232). Developed on Tempus’ xT platform, the CDx will be used to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be eligible for treatment with navtemadlin.
READ PRESS RELEASEGet customized solutions for your needs.